Targeted Medical Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRGM research report →
About the company
Targeted Medical Pharma, Inc. , a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy.
- CEO
- Cameron Tymstra
- IPO
- 2012
- Employees
- 30
- HQ
- Los Angeles, CA, US
Price Chart
- Market Cap
- $302
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -3.13
- Div Yield
- 0.00%
- Gross Margin
- 60.17%
- Op Margin
- -38.58%
- Net Margin
- -57.86%
- ROE
- 26.62%
- ROIC
- 26.62%
- Revenue
- $5.26M · -26.03%
- Net Income
- $-3,043,810 · 21.85%
- EPS
- $-0.11 · 26.67%
- Op Income
- $-2,029,773
- FCF YoY
- -263.86%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -52.42
- Avg Volume
- 46
AI snapshot
Six angles, distilled from the data.
The stock remains in a deep long-term downtrend and sits pinned near its 52-week low, far below the 200-day average. That setup favors a distressed, speculative regime rather than a durable trend reversal, with any bounce still needing to reclaim the long-term moving average first.
No analyst consensus or price target is available, and there have been no recent rating changes. The setup is effectively coverage-light, so shareholders should watch for any new initiation or target reset to gauge outside conviction.
Earnings have not produced a beat in the last eight reported quarters, with a 0/8 record. Revenue is still contracting 9% year over year, so the key watchpoint is whether losses and cash burn stabilize rather than any near-term upside surprise.
No discretionary insider buying or selling stands out. The recent filings are award-type grants to directors, which are compensation-related rather than conviction signals, so the pattern reads as neutral.
Profitability remains weak despite a 60.2% gross margin, with a -28.48% operating margin and -57.86% net margin. Revenue fell 9% year over year, while free cash flow was -$1.28 million, underscoring ongoing operating strain.
Against specialty pharma peers, the company looks smaller, more distressed, and far less liquid than established names. With no consensus valuation and a micro-cap market value of $302, it trades as a deep-speculation situation rather than a sector comp.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 4, 16 | DEWALD MAURICE J | other | 200,000 |
| Mar 4, 16 | DEWALD MAURICE J | other | 100,000 |
| Jul 22, 13 | Gottlieb Scott | other | 25,000 |
| Jul 22, 13 | Gottlieb Scott | other | 25,000 |
| Jul 22, 13 | Gottlieb Scott | other | 0 |
| Jul 22, 13 | DEWALD MAURICE J | other | 25,000 |
| Jul 22, 13 | DEWALD MAURICE J | other | 25,000 |
| Mar 1, 13 | DEWALD MAURICE J | other | 50,000 |
Our TRGM coverage
Recent articles, reports, and earnings notes.
No research on TRGM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRGM report →Similar companies
Peers in the same neighborhood.
AI analysis · Last refreshed July 2, 2026 · Live quote · Not investment advice